Antihypertensive therapy
1 paper2 findings
- Funder: National Institute on Aging
- In silico1
Outcomes
2Cost-effectiveness
upin silico1
1 study
Cost-effectiveness
upin silico1
Antihypertensive therapy improves cost-effectiveness in silico (ICER ¥22,489 per QALY in 40s).
In silicoscreening-detected hypertension20-year horizon
Hypertension research : official journal of the Japanese Society of Hypertension19 Aug 2026
Quality-adjusted life-years
upin silico1
1 study
Quality-adjusted life-years
upin silico1
Antihypertensive therapy improves quality-adjusted life-years in silico (13.52 vs 12.85 QALYs).
In silicoscreening-detected hypertension20-year horizon
Hypertension research : official journal of the Japanese Society of Hypertension19 Aug 2026
Funding
1 grant since 2022National Institute on AgingUS$909.2k
Latest
1 in 12 monthsHypertension Research
Cost-effectiveness analysis of early antihypertensive treatment for hypertension detected at health screening
Computational studyHypertension